vs
BYLINE BANCORP, INC.（BY）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是BYLINE BANCORP, INC.的1.1倍（$127.1M vs $112.4M），再鼎医药同比增速更快（17.1% vs 9.0%），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BY vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$112.4M
营收增速更快
ZLAB
高出8.1%
9.0%
两年增速更快
ZLAB
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $127.1M |
| 净利润 | $37.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 33.4% | — |
| 营收同比 | 9.0% | 17.1% |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | $0.83 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYZLAB
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $127.1M | ||
| Q3 25 | $115.7M | $115.4M | ||
| Q2 25 | $110.5M | $109.1M | ||
| Q1 25 | $103.1M | $105.7M | ||
| Q4 24 | $104.7M | $108.5M | ||
| Q3 24 | $101.8M | $101.8M | ||
| Q2 24 | $99.4M | $100.1M |
净利润BYZLAB
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $-36.0M | ||
| Q2 25 | $30.1M | $-40.7M | ||
| Q1 25 | $28.2M | $-48.4M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-41.7M | ||
| Q2 24 | $29.7M | $-80.3M |
毛利率BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -54.6% | ||
| Q3 25 | 43.1% | -42.3% | ||
| Q2 25 | 35.2% | -50.3% | ||
| Q1 25 | 36.4% | -53.3% | ||
| Q4 24 | 38.6% | -62.6% | ||
| Q3 24 | 39.3% | -66.6% | ||
| Q2 24 | 40.4% | -76.0% |
净利率BYZLAB
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | -31.2% | ||
| Q2 25 | 27.2% | -37.3% | ||
| Q1 25 | 27.4% | -45.8% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -40.9% | ||
| Q2 24 | 29.9% | -80.2% |
每股收益（稀释后）BYZLAB
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-0.05 | ||
| Q3 25 | $0.82 | $-0.03 | ||
| Q2 25 | $0.66 | $-0.04 | ||
| Q1 25 | $0.64 | $-0.04 | ||
| Q4 24 | $0.68 | $-0.09 | ||
| Q3 24 | $0.69 | $-0.04 | ||
| Q2 24 | $0.68 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $715.5M |
| 总资产 | $9.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BYZLAB
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $689.6M | ||
| Q3 25 | $259.0M | $717.2M | ||
| Q2 25 | $218.3M | $732.2M | ||
| Q1 25 | $421.3M | $757.3M | ||
| Q4 24 | $563.1M | $779.7M | ||
| Q3 24 | $452.6M | $616.1M | ||
| Q2 24 | $730.5M | $630.0M |
股东权益BYZLAB
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $715.5M | ||
| Q3 25 | $1.2B | $759.9M | ||
| Q2 25 | $1.2B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M |
总资产BYZLAB
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $1.2B | ||
| Q3 25 | $9.8B | $1.2B | ||
| Q2 25 | $9.7B | $1.2B | ||
| Q1 25 | $9.6B | $1.2B | ||
| Q4 24 | $9.5B | $1.2B | ||
| Q3 24 | $9.4B | $985.3M | ||
| Q2 24 | $9.6B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-26.0M | ||
| Q3 25 | $38.3M | $-32.0M | ||
| Q2 25 | $16.3M | $-31.0M | ||
| Q1 25 | $27.1M | $-61.7M | ||
| Q4 24 | $175.2M | $-55.8M | ||
| Q3 24 | $19.8M | $-26.8M | ||
| Q2 24 | $40.1M | $-42.2M |
自由现金流BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-26.7M | ||
| Q3 25 | $38.0M | $-35.0M | ||
| Q2 25 | $15.2M | $-33.9M | ||
| Q1 25 | $25.0M | $-63.2M | ||
| Q4 24 | $171.2M | $-58.4M | ||
| Q3 24 | $19.1M | $-28.2M | ||
| Q2 24 | $39.4M | $-42.9M |
自由现金流率BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -21.0% | ||
| Q3 25 | 32.8% | -30.4% | ||
| Q2 25 | 13.7% | -31.1% | ||
| Q1 25 | 24.3% | -59.9% | ||
| Q4 24 | 163.5% | -53.8% | ||
| Q3 24 | 18.8% | -27.7% | ||
| Q2 24 | 39.7% | -42.9% |
资本支出强度BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 3.8% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% |
现金转化率BYZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BY
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
